



Cite this: *Green Chem.*, 2016, **18**, 4189

## Development of an *E. coli* strain for one-pot biofuel production from ionic liquid pretreated cellulose and switchgrass†

Marijke Frederix,<sup>a,b</sup> Florence Mingardon,<sup>c</sup> Matthew Hu,<sup>a,b</sup> Ning Sun,<sup>b,d</sup> Todd Pray,<sup>b,d</sup> Seema Singh,<sup>a,b,e</sup> Blake A. Simmons,<sup>a,b,e</sup> Jay D. Keasling<sup>a,b,f,g</sup> and Aindrila Mukhopadhyay<sup>\*a,b</sup>

Biological production of chemicals and fuels using microbial transformation of sustainable carbon sources, such as pretreated and saccharified plant biomass, is a multi-step process. Typically, each segment of the workflow is optimized separately, often generating conditions that may not be suitable for integration or consolidation with the upstream or downstream steps. While significant effort has gone into developing solutions to incompatibilities at discrete steps, very few studies report the consolidation of the multi-step workflow into a single pot reactor system. Here we demonstrate a one-pot biofuel production process that uses the ionic liquid 1-ethyl-3-methylimidazolium acetate ([C<sub>2</sub>C<sub>1</sub>Im][OAc]) for pretreatment of switchgrass biomass. [C<sub>2</sub>C<sub>1</sub>Im][OAc] is highly effective in deconstructing lignocellulose, but nonetheless leaves behind residual reagents that are toxic to standard saccharification enzymes and the microbial production host. We report the discovery of an [C<sub>2</sub>C<sub>1</sub>Im]-tolerant *E. coli* strain, where [C<sub>2</sub>C<sub>1</sub>Im] tolerance is bestowed by a P7Q mutation in the transcriptional regulator encoded by *rcdA*. We establish that the causal impact of this mutation is the derepression of a hitherto uncharacterized major facilitator family transporter, YbjJ. To develop the strain for a one-pot process we engineered this [C<sub>2</sub>C<sub>1</sub>Im]-tolerant strain to express a recently reported  $\Delta$ -limonene production pathway. We also screened previously reported [C<sub>2</sub>C<sub>1</sub>Im]-tolerant cellulases to select one that would function with the range of *E. coli* cultivation conditions and expressed it in the [C<sub>2</sub>C<sub>1</sub>Im]-tolerant *E. coli* strain so as to secrete this [C<sub>2</sub>C<sub>1</sub>Im]-tolerant cellulase. The final strain digests pretreated biomass, and uses the liberated sugars to produce the bio-jet fuel candidate precursor  $\Delta$ -limonene in a one-pot process.

Received 4th March 2016,  
Accepted 11th April 2016  
DOI: 10.1039/c6gc00642f

www.rsc.org/greenchem

## Introduction

Sustainably grown lignocellulosic biomass provides an attractive carbon source for the production of renewable biofuels.<sup>1</sup> Prior to saccharification, pretreatment of the biomass is required to separate it from the lignin and to solubilize the available cellulose and hemicellulose to make it more accessible to enzymes that hydrolyze it into fermentable sugars.

Pretreatment is traditionally done *via* techniques like exposure to dilute acids or bases at elevated temperatures or using ammonia fiber expansion.<sup>2</sup> More recently however, hydrophilic ionic liquids (ILs) such as 1-ethyl-3-methylimidazolium acetate ([C<sub>2</sub>C<sub>1</sub>Im][OAc]) have emerged as highly effective pretreatment solvents that are more environmentally friendly, produce relatively low amounts of biomass-derived inhibitors and can be used at lower temperatures and pressures than conventional pretreatments that use acids or bases.<sup>3–5</sup> One of the initial challenges in the use of ILs as pretreatment reagents was the cost of the reagents, and for an economical process the ILs had to be recovered and recycled, leaving less than 12 mM in a typical slurry.<sup>6</sup> Significant improvements in IL synthesis have reduced their cost and current predictions estimate that in an economical industrial-scale production process, a residual level of 12–300 mM can be allowed to remain in the downstream sugar stream that will be used for cultivation of the biofuel-producing organism.<sup>6,7</sup> Consequently, both the saccharification enzymes as well as the microbiological conversion have to be optimized to be able to accommodate the pres-

<sup>a</sup>Joint BioEnergy Institute, Emeryville, CA, USA. E-mail: amukhopadhyay@lbl.gov

<sup>b</sup>Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

<sup>c</sup>Total New Energies Inc., Emeryville, CA, USA

<sup>d</sup>Advanced Biofuels Process Demonstration Unit, Emeryville, CA, USA

<sup>e</sup>Biological and Engineering Sciences Center, Sandia National Laboratories, Livermore, CA, USA

<sup>f</sup>Department of Chemical & Biomolecular Engineering, University of California, Berkeley, CA 94720, USA

<sup>g</sup>Department of Bioengineering, University of California, Berkeley, CA 94720, USA

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c6gc00642f



ence of higher levels of residual ILs. To this end, several studies have focused on both the discovery of IL-tolerant microbes<sup>8</sup> as well as cellulases that can function in the presence of high levels of ILs.<sup>9,10</sup> However, as with any process that requires purified proteins, the cost of the proteins remains a significant source of cost.

Recent progress in consolidated bioprocessing addresses the cost of the saccharification enzymes and has led to the development of a variety of strains that express cellulase enzymes<sup>11,12</sup> and in some examples are also coupled to a production pathway.<sup>13–15</sup> However, these engineered strains will also be hampered by growth inhibitory compounds that are routinely present in pretreated hydrolysates,<sup>16</sup> making the use of industrially relevant hydrolysates challenging. In the case of IL pretreated hydrolysates, the toxicity of residual ILs to the microbial production host<sup>17</sup> is the major challenge to optimizing an integrated process, and has led to studies that focus on discovery of tolerance bestowing mechanisms<sup>18</sup> and strain engineering to optimize the expression of such genes.<sup>19</sup> A necessary next step in the area of biofuel production is to consolidate the findings from studies that have examined and found solutions to different segments of the bioconversion process, from cellulases that may allow efficient saccharification in IL-containing hydrolysate,<sup>9</sup> strains that can withstand residual ILs<sup>8</sup> and synthetic metabolic pathways that convert the biomass-derived sugars to desirable final products.<sup>20</sup>

In this study, we characterized a spontaneous *E. coli* mutant that is tolerant to the IL 1-ethyl-3-methylimidazolium chloride ( $[C_2C_1Im]Cl$ ), and identify the causal mutation to be located in the transcriptional regulator RcdA (also known as YbjK). We examined the genetic basis for the phenotype observed due to the mutant RcdA and demonstrated the ability of an *rcdA* mutant to produce fuels in IL containing medium and with IL pretreated biomass as the carbon source. Subsequently we screened a mini-library of secreted cellulases for their ability to confer growth on cellulose in the presence of ILs and integrated the best cellulase for our cultivation conditions into an *E. coli rcdA* mutant strain also engineered to contain a production pathway for the monoterpene bio-jet fuel precursor and commodity chemical,  $\alpha$ -limonene (Fig. 1). Terpene-based

compounds provide a range of candidates with energy content and combustion properties that make them suitable for gasoline, diesel as well as jet fuel needs.<sup>21,22</sup> These advanced bio-fuels also have physicochemical properties that may align better with the existing infrastructure. Since *E. coli* DH1 has previously been shown to be an ideal host for monoterpene production,<sup>20</sup> we first constructed an *rcdA* mutant in this strain background. This strain was able to produce significant levels of  $\alpha$ -limonene in  $[C_2C_1Im][OAc]$  containing growth medium and with either phosphoric acid swollen cellulose (PASC) or  $[C_2C_1Im][OAc]$  pretreated switchgrass as a carbon source. This study demonstrates the one-pot biofuel production process for IL pretreated biomass, using an IL tolerant *E. coli* strain and takes into account the reduced requirement for IL recycling.


## Experimental

### Bacterial strains and plasmids

All strains and plasmids used in this work can be obtained from <http://public-registry.jbei.org><sup>23</sup> and are summarized in Table 1. *E. coli* DH10B (Invitrogen Carlsbad, CA) was used for cloning. All  $[C_2C_1Im]Cl$  and  $[C_2C_1Im][OAc]$  tolerance assays were done using *E. coli* BW25113-derived strains.<sup>24</sup> The original FM002 strain was isolated from colonies of spontaneous mutants that appeared after plating FM001 on plates containing  $[C_2mim^+]Cl^-$ . The kanamycin resistance cassette of the KEIO collection *E. coli* strains, BW25113 *rcdA* and BW25113 *ompA*, was removed using the plasmid pCP20, per methods described in Cherepanov *et al.*<sup>25</sup> to generate the strains JBEI-12574 and JBEI-13315. An *E. coli* DH1 (ATCC33849) derived *rcdA* mutant strain (JBEI-13314) was generated using the lambda red methodology<sup>26</sup> and was used as a host strain for  $\alpha$ -limonene production. All plasmids constructed in this study were designed using the j5 DNA assembly design software<sup>27</sup> and were assembled using the method described by Gibson *et al.*<sup>28</sup>

### Growth conditions and media

All *E. coli* strains expressing cellulases or the limonene production pathway were grown at 30 °C, while all other strains were grown at 37 °C. The medium used was Luria-Bertani (LB) or EZ rich minimal medium (Teknova, Hollister, CA). When PASC<sup>29</sup> was used as carbon source it was added to EZ rich to obtain a final concentration of 10 g per L cellulose (equivalent to 11 g glucose per L). For hydrolysate-derived medium,  $[C_2C_1Im][OAc]$ -treated biomass (prepared at the ABPDU per methods described below) was added to obtain a final glucose concentration of 10 g per L and 2.3 g per L xylose. Cultures with pCellulose and pCellulose-derived plasmids (Table 1) were always grown in the presence of 10 g per L glucose at 30 °C to repress transcriptional activity from the *cspD* promoter, unless PASC was used as the carbon source. All chemicals were purchased from Sigma-Aldrich (St Louis, MO). Antibiotics were added as required to maintain plasmid selection.  $[C_2mim^+]Cl^-$  (98%) was purchased from Sigma-Aldrich (St Louis, MO) and



**Fig. 1** *E. coli* engineered for a one-pot limonene production process from IL pretreated biomass. An *E. coli rcdA* mutant is more tolerant to the extracellular presence of ILs due to the overexpression of the major facilitator superfamily transporter *ybjJ*. To produce limonene from unsaccharified cellulose (PASC), the strain was engineered to contain a  $\alpha$ -limonene production plasmid and to secrete the IL tolerant cellulase (J29) into the extracellular medium.



Table 1 Strains and plasmids used in this study

	Description	Ref.
<b>Strains</b>		
JBEI-12929	FM001, <i>E. coli</i> BW25113 $\Delta dmsD$ + pBbA8c-RFP	This work
JBEI-7851	FM002, spontaneous mutant tolerant to 200 mM [C <sub>2</sub> C <sub>1</sub> Im]Cl derived from <i>E. coli</i> BW25113 $\Delta dmsD$ + pBbA8c-RFP, P7Q mutation	This work
JW5114	<i>E. coli</i> BW25113 <i>rcdA</i> (b0846) mutant	24
JW0829	<i>E. coli</i> BW25113 <i>ybjj</i> (b0845) mutant	24
JW0940	<i>E. coli</i> BW25113 <i>ompA</i> (b0957) mutant	24
JW1010	<i>E. coli</i> BW25113 <i>pgaA</i> (b1024) mutant	24
JW1023	<i>E. coli</i> BW25113 <i>csgD</i> (b1040) mutant	
JW1529	<i>E. coli</i> BW25113 <i>ydeI</i> (b1536) mutant	24
JW5778	<i>E. coli</i> BW25113 <i>nanC</i> (b4311) mutant	
JW1151	<i>E. coli</i> BW25113 <i>ycgZ</i> (b1164) mutant	24
JW5826	<i>E. coli</i> BW25113 <i>asr</i> (b1597) mutant	24
JW2095	<i>E. coli</i> BW25113 <i>yeHA</i> (b2108) mutant	24
JW1022	<i>E. coli</i> BW25113 <i>csgE</i> (b1039) mutant	24
JBEI 13314	<i>E. coli</i> DH1 <i>rcdA</i> mutant	This work
JBEI-13315	<i>E. coli</i> BW25113 <i>ompA</i> (b0957) mutant, Km cassette removed using pCP20	This work
JBEI-12574	<i>E. coli</i> BW25113 <i>rcdA</i> (b0846) mutant, Km cassette removed using pCP20	This work
<b>Plasmids</b>		
JBEI-6409	pLimonene, limonene production plasmid	20
JBEI-7585	pCP20, plasmid to remove Km resistance cassette from KEIO collection	26
JBEI-2558	pBbS8k (low copy vector with arabinose inducible promoter)	56
JBEI-4338	pCellulose	15
JBEI-12905	pCellulose/J24	This work
JBEI-12906	pCellulose/J29	This work
JBEI-12934	pCellulose/J20	This work
JBEI-12940	pCellulose/Csac	This work
JBEI-12935	pBbS8k- <i>ybjj</i>	This work
JBEI-12927	pBbS8k- <i>ompA</i>	This work
JBEI-12925	pBbS8k- <i>ybjj-ompA</i>	This work

[C<sub>2</sub>mim<sup>+</sup>][OAc] (90%) was purchased from BASF (Ludwigshafen, Germany).

### Growth assays

To measure growth, 5  $\mu$ l of preculture was inoculated into 100  $\mu$ l of growth medium in 96-well plates and grown at 30 °C in a Tecan F200 microtiterplate reader (Maennedorf, Switzerland), measuring the optical density at a wavelength of 590 nm (OD<sub>590</sub>) at 20 min intervals. When PASC and IL-pretreated biomass were used as a carbon source, because of the turbidity of the growth medium, growth was measured by counting colony forming units (CFU). 4 mL of culture was inoculated with 100  $\mu$ l of fresh preculture, grown shaking at 30 °C, and CFU was determined by counting the number of colonies after plating 100  $\mu$ l of a 10<sup>-6</sup> dilution on LB-agar plates.

### Whole-genome resequencing

DNA from FM001 and FM002 was randomly sheared into ~400 bp fragments that were used to create Illumina libraries. These libraries were sequenced on Illumina sequencers, generating 100 bp paired-end reads that were aligned to the reference genome (GenBank accession number NC\_000913) using the Burrows–Wheeler alignment tool<sup>30</sup> and down sampled to generate an average read depth of 250 times. A total of 55 putative variants were identified using the samtools and mpileup programs.<sup>31</sup> Variants that failed our filtering criteria (minimum quality = 10, minimum *P* value for strand bias = 0.0001,

minimum *P* value for end bias = 0.0001, single-nucleotide polymorphisms within 10 bp around a gap) were removed from the analysis. There was only one single base pair that was different between FM001 and FM002, a C20A mutation in the gene *rcdA* leading to a P7Q mutation in the amino acid sequence.

### Limonene production assays

The *E. coli* DH1 *rcdA* mutant (JBEI 13314) was used for all limonene production assays. Strains harboring the limonene production plasmid (JBEI-6409) were grown in EZ-Rich medium with the appropriate antibiotics to maintain plasmid selection, with glucose, PASC, or IL-pretreated biomass hydrolysate as a carbon source at a final concentration of 1% (10 g L<sup>-1</sup>) (Teknova, Hollister, CA). Precultures (from fresh transformation plates) were grown shaking overnight at 30 °C and used to inoculate production cultures at a starting optical density (OD<sub>600</sub>) of 0.1. Cultures containing glucose or IL-pretreated biomass hydrolysate as carbon source were then grown at 30 °C until OD<sub>600</sub> between 0.6–0.8 and induced with 25  $\mu$ M isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG), at which point a dodecane overlay (10 mL for 50 mL cultures) was also added to capture the produced limonene. Limonene production was sampled after 48 h and analyzed using gas-chromatography mass-spectrometry (GC-MS) according to methods described previously.<sup>20</sup> Cultures containing PASC as carbon source were grown for 8 hours with no [C<sub>2</sub>mim<sup>+</sup>][OAc] present and then for 10 hours with 100 mM [C<sub>2</sub>mim<sup>+</sup>][OAc], after which they were



induced with 25  $\mu\text{M}$  IPTG, overlaid with dodecane (10 mL for 50 mL cultures) and allowed to grow for 48 h before sampling and GC-MS analysis for limonene production.


### Preparation of the hydrolysate using IL pretreated biomass

The hydrolysate was prepared using pilot-scale reactors at the DOE Advanced Biofuels Process Demonstration Unit (ABPDU), Lawrence Berkeley National Laboratory.<sup>32</sup> Switchgrass was pretreated in a 210 L customized Andritz reactor at  $160 \pm 3$  °C for 2 h using  $[\text{C}_2\text{C}_1\text{Im}][\text{OAc}]$  as the solvent. The total mass of the reaction was 40 kg with 15% (w/w) solid loading. After 2 h incubation, the reactor was cooled to 60 °C and 40 L ethanol was pumped into the mixture as the anti-solvent. The slurry was released from the reactor and homogenized using a laboratory blender to break down large chunks. The solid was then separated from the IL-rich liquid by filtration through cheese cloth. The recovered solid was further washed with warm water (60 °C) to remove the IL residual. The washed solids were collected to determine moisture content and solid recovery from IL pretreatment. Enzymatic saccharification was performed in 50L IKA SPP50 reactor with 15% (w/w) solid loading. The total batch mass was 20 kg with cellulase (CTec2) 54 mg enzyme per g glucan and xylanase (HTec2) 6 mg enzyme per g glucan (total protein loading: 9.2 mg protein per g glucan). After 160 h incubation, the reaction was stopped and the slurry was transferred out. The lignin rich solid was separated from the hydrolysate using a basket centrifuge with a polypropylene filter bag (pore size 25–30 micron) as the liner. The hydrolysate was stored at 4 °C for future use and analysis.

## Results and discussion

### Isolation of a spontaneous IL tolerant mutant

Selected mutants from the *E. coli* KEIO collection were screened for strains with increased tolerance to  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$ . While none of the KEIO mutants in this screen were significantly more or less tolerant than wild type, we did observe the appearance of spontaneous mutants with the desired phenotype. One of these mutants (FM002), found in the  $\Delta\text{dmsD}$  mutant (FM001), had a very reproducible IL tolerant phenotype (Fig. S1A and B†). Further study showed that in addition to increased tolerance to 200 mM  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$  it also had increased tolerance to 150 mM  $[\text{C}_2\text{C}_1\text{Im}][\text{OAc}]$ , a related IL. This suggests that the tolerance is related to the  $[\text{C}_2\text{C}_1\text{Im}]^+$  cation (Fig. S1C and D†). The genetic basis of the increased tolerance phenotype of FM002 was identified *via* whole genome resequencing and indicated one original mutation in basepair 20 (C20A) of the transcriptional regulator *rcdA* (b0846), which resulted in a P7Q amino acid change. Bioinformatics analysis of the RcdA protein sequence showed that this mutation is at the start of the helix-turn-helix DNA binding domain of the protein. Considering the biochemical nature of proline (hydrophobic with a strong conformational rigidity) to glutamine (polar) change, we hypothesized that the identified mutation renders RcdA non-functional. To verify this, the



**Fig. 2** Growth of strains BW25113 (WT) and a BW25113  $\Delta\text{rcdA}$  mutant in the presence of  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$ . Growth of different strains in LB medium, (A) without  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$  or (B) containing 200 mM  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$ . Shaded areas represent standard deviations from at least three biological replicates.

*rcdA* mutant from the KEIO collection was tested for tolerance to  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$  and indeed found to be more tolerant than wild type BW25113 (Fig. 2). As was the case for FM002, the BW25113 *rcdA* mutant was also found to be tolerant to  $[\text{C}_2\text{C}_1\text{Im}][\text{OAc}]$  (Fig. S1E and F†).


### Phenotypic characterization of RcdA regulatory targets

Since RcdA is a transcriptional regulator, the increased tolerance phenotype of the *rcdA* mutant was hypothesized to be due to its regulatory targets. The RcdA binding box and its potential targets had already been determined *via* a genomic SELEX screening procedure in *E. coli* BW25113 by Shimada *et al.*<sup>33</sup> The presence of 20 RcdA binding sites in the genome had led to the prediction of 27 putative gene regulatory targets. A subset of these was selected for further analysis, based on their predicted function. Amongst these were two transcriptional regulators *appY* and *ycgF*, which have been shown to be involved in stress response,<sup>34,35</sup> two cytoplasmic stress response genes *ydeI* and *asr*,<sup>36,37</sup> several genes involved in biofilm formation (*csgD*, *csgB*, *yehA*, *fimB*),<sup>38–40</sup> an inner membrane protein *ybjJ*, which is located next to *rcdA* and is predicted to be a transporter of the major facilitator superfamily (MFS), and three pore-forming outer membrane proteins (*ompA*, *pgaA* and *nanC*).<sup>41–43</sup> The mutants for these genes were obtained from the KEIO collection<sup>24</sup> and screened for their potential involvement in  $[\text{C}_2\text{C}_1\text{Im}]^+$  tolerance by a liquid growth assay in 96 well plates in the presence of 200 mM  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}$  (Fig. S2A–D†). This led to the identification of two mutants with reduced tolerance to  $[\text{C}_2\text{C}_1\text{Im}]\text{Cl}^-$ ,  $\Delta\text{ompA}$  and  $\Delta\text{ybjJ}$ , both of which encode proteins involved in transport across the inner and outer membrane (Fig. 3).

### Overexpression of YbjJ and OmpA

*YbjJ* is an inner membrane transporter and *OmpA* an outer membrane porin and both may impact  $[\text{C}_2\text{C}_1\text{Im}]^+$  tolerance individually, or together as a complex. To evaluate these hypotheses, both genes were overexpressed separately (JBEI-12935 and JBEI-12927 respectively) and together in an operon





**Fig. 3** Growth of strains BW25113 (WT), a BW25113  $\Delta ompA$  and a BW25113  $\Delta ybjJ$  mutant in the presence of  $[C_2C_1Im]Cl$ . Growth of strains in LB medium, (A) without  $[C_2C_1Im]Cl$  or (B) containing 200 mM  $[C_2C_1Im]Cl$ . Shaded areas represent standard deviations from at least three biological replicates.

(JBEI-12925), on a low copy plasmid transcribed from the arabinose-inducible *araBAD* promoter ( $P_{BAD}$ ). They were subsequently introduced into wild type BW25113 and their growth in the presence of 200 mM  $[C_2C_1Im]Cl$  was evaluated in a liquid growth assay in 96 well plates (Fig. 4A and B). Overexpression of OmpA and YbjJ in an operon increased tolerance significantly, as did overexpression of YbjJ on its own. However, overexpression of OmpA did not increase tolerance, but rather led to a growth burden that was further increased in the presence of  $[C_2C_1Im]Cl$ . However, in strains overexpressing YbjJ alone, native levels of OmpA are still present in wild type *E. coli* BW25113 and may still have synergistic benefit in the function. To fully eliminate the possibility that YbjJ requires OmpA for function, YbjJ was overexpressed in a  $\Delta ompA$  mutant. The resulting strain was found to have increased tolerance to  $[C_2C_1Im]Cl$  equivalent to the overexpression of YbjJ in the wild type *E. coli* BW25113, showing that the YbjJ on its own is sufficient for tolerance.

#### Production of fuels in the presence of $[C_2C_1Im][OAc]$


To evaluate if the *rcdA* mutant could be used for biofuel production from IL-pretreated biomass, we generated an *rcdA* deletion mutant in *E. coli* DH1, since this is the preferred

production host for terpenes.<sup>44</sup> The main goal of this study was to use IL-pretreated biomass for fuel production, therefore we chose to conduct all fuel production assays with  $[C_2C_1Im][OAc]$ , one of the most effective ILs established for biomass pretreatment.<sup>45</sup>

First we confirmed tolerance of the *E. coli* DH1 *rcdA* mutant to  $[C_2C_1Im][OAc]$  using plate growth assays (Fig. S3†). Then we developed the strain to produce the terpene jet-fuel precursor candidate  $\alpha$ -limonene and determined the production using either glucose or switch grass hydrolysate as the carbon source (Fig. 5A). In optimal conditions using glucose as a carbon source and without toxicity from  $[C_2C_1Im][OAc]$ , an *E. coli* DH1  $\alpha$ -limonene producer strain carrying the plasmid pLimonene<sup>20</sup> yields about  $\sim 550 \text{ mg L}^{-1}$ . In the presence of 100 mM  $[C_2C_1Im][OAc]$  this strain shows limited growth and no  $\alpha$ -limonene could be detected. In contrast, the *E. coli* DH1 *rcdA* mutant  $\alpha$ -limonene producer strain produced  $\sim 300 \text{ mg L}^{-1}$  in the presence of  $[C_2C_1Im][OAc]$  (Fig. 5A).


We also evaluated the ability of both strains to produce limonene in EZ rich media containing IL pretreated and saccharified switchgrass as a carbon source. IL pretreated switchgrass was generated at the ABPDU, based on a standard process as described in the Methods section, and involved extensive washing leading to a final residual  $[C_2C_1Im][OAc]$  concentration of 12 mM. No toxicity was observed when the biofuel production strains were grown in hydrolysate-derived growth medium compared to glucose-derived growth medium. Using this hydrolysate-containing media, a yield of  $\sim 400 \text{ mg per L}$   $\alpha$ -limonene was obtained for both wild type and the *rcdA* mutant.

To test if the strains could produce limonene in IL pretreated biomass that contains toxic levels of  $[C_2C_1Im][OAc]$ , the IL was added as described in the Methods section. In this test, no growth or production was observed in the wild type producer strain (Fig. 5A). However the *rcdA* mutant producer produced approximately 150 mg per L  $\alpha$ -limonene, which is comparable to the production with glucose and no  $[C_2C_1Im][OAc]$  in the media. To our knowledge, this is the first report of producing an advanced biofuel directly from a solution containing IL pretreated biomass.



**Fig. 4** Growth of wild type BW25113 (WT) expressing pBbS8k, pBbS8k-ybjJ, pBbS8k-ompA, pBbS8k-ybjJ-ompA and pBbS8k-ompA and a BW25113  $\Delta ompA$  mutant ( $\Delta ompA$ ) expressing pBbS8k-ybjJ in the presence of  $[C_2C_1Im]Cl$ . Growth of strains in LB medium (A) without  $[C_2C_1Im]Cl$  or (B) containing 200 mM  $[C_2C_1Im]Cl$ . Shaded areas represent standard deviations from at least three biological replicates.






**Fig. 5** Limonene production in wild type *E. coli* DH1 and a DH1  $\Delta rc d A$  mutant using different carbon sources. (A) Limonene yield comparison in defined growth medium using (A) glucose (blue) or IL-pretreated biomass (red), and (B) PASC (green) as carbon source in the presence and absence of 112 mM and 100 mM  $[C_2C_1Im][OAc]$  respectively.

### One-pot biofuel production process in $[C_2C_1Im]^+$ containing medium

In the cellulosic biofuel production workflow, after pretreatment of biomass, the solubilized cellulose needs to be converted into glucose by cellulases. Traditionally this is done in a separate step using purified enzymes, but it can also be done through a consolidated process in which the required cellulases have been engineered into the biofuel production host. In previous work<sup>15</sup> a cellulose degrading plasmid, pCellulose, had been developed for the expression of a secreted cellulase (a translational fusion between the N-terminus of the *E. coli* protein OsmY and Cel from *Bacillus* D04) and an intracellular  $\beta$ -glucosidase (Cel3A from *Cellvibrio japonicas*) by expressing them from native *E. coli* promoters (*pcspD* and *pwrBA* respectively) (Fig. 1 and Table 1). These enzymes had not been tested for activity in the presence of  $[C_2C_1Im][OAc]$ . We transformed pCellulose into BW25113 and the BW25113 *rcdA* mutant, and tested the ability to grow on medium containing PASC as a carbon source. While pCellulose did allow growth in culture medium without  $[C_2C_1Im][OAc]$ , the growth rates were significantly lower than previously reported. In the presence of  $[C_2C_1Im][OAc]$ , the *rcdA* mutant grew slightly better than the WT, but never to the same level as the control without  $[C_2C_1Im][OAc]$ , indicating that the enzymes in pCellulose might not perform optimally under these conditions (Fig. 6A, B), and that the Cel enzyme may be sensitive to  $[C_2C_1Im][OAc]$ .

To overcome the potential toxicity of  $[C_2C_1Im][OAc]$  to cellulases, we took advantage of the collection of IL-tolerant cellulases that had been assembled by Gladden *et al.*<sup>9</sup> We evaluated four  $[C_2C_1Im][OAc]$  tolerant cellulases for their ability to confer growth on PASC in the presence of  $[C_2C_1Im][OAc]$ : J24 (*Paenibacillus provencensis*), J29 (*Paenibacillus* sp. KSM-N546), J30 (*Thermobacillus composti* KWC4) and Csac (*Caldicellulosiruptor saccharolyticus*).<sup>9,46</sup> To evaluate their potential consolidated with a production strain, variants of pCellulose plasmid were constructed in which *cel* was replaced by the genes encoding the IL tolerant cellulases (Table 1). These plasmids were sub-



**Fig. 6** Growth of BW25113 (WT) and the BW25113  $\Delta rc d A$  mutant containing pCellulose variants on defined medium containing glucose (A, C) or PASC (B, D) as carbon source. A, B: pCellulose, C, D: pCellulose-J24, pCellulose-J29, pCellulose-J30 and pCellulose-Csac.



sequently transformed to BW25113 and the BW25113 *rcdA* mutant and the growth on PASC derived medium was assayed by CFU counting assays. All strains showed equivalent growth on glucose as a carbon source (Fig. 6C).

When expressed in the *rcdA* mutant, one pCellulose derivative, pCellulose-J29 outperformed the others. No significant growth difference was observed in the presence and absence of  $[C_2C_1Im][OAc]$ , indicating that J29 is adequately produced, secreted and active in our cultivation conditions (Fig. 6D). Next,  $\alpha$ -limonene production using PASC as an unsaccharified carbon source was evaluated by transforming the *E. coli* DH1 pLimonene control strain and the *E. coli* DH1 *rcdA* pLimonene strain with the pCellulose-J29 plasmid. In the absence of  $[C_2C_1Im][OAc]$ , both control and the *rcdA* mutant produce approximately 35 mg per L  $\alpha$ -limonene. In the presence of 150 mM  $[C_2C_1Im][OAc]$ , no growth or fuel production was observed for the control, but a yield of 10 mg L<sup>-1</sup> was obtained for the *rcdA* mutant production strain (Fig. 5B).

## Conclusions

The major contribution of this study is the development of a one-pot biofuel production process that can directly convert both saccharified IL-pretreated hydrolysate and unsaccharified cellulose into a next-generation bio-jet fuel precursor in the presence of ILs. In contrast to previous studies that used highly washed pretreated biomass,<sup>15</sup> significant IL was included in the growth medium, as would be expected in a typical industrial process that uses IL based pretreatment and provides an important baseline for production under industrially relevant conditions.<sup>6,7</sup> For a successful process, two aspects of IL toxicity needed to be overcome: both the biofuel production strain and the secreted cellulases that convert the solubilized cellulose into fermentable sugars were required to be IL-tolerant.

To overcome the first challenge, a spontaneous  $[C_2C_1Im]$  tolerant mutant strain of *E. coli* BW25113 was used. Analysis of the isolated mutant identified a mutation in the transcriptional regulator RcdA. We used the *E. coli* DH1 *rcdA* mutant as our background for growth in medium containing saccharified  $[C_2C_1Im]$  pretreated biomass as carbon source in the presence of the  $[C_2C_1Im]$  reagent, and demonstrated the production of the bio-jet fuel precursor  $\alpha$ -limonene, at final titer of 150 mg L<sup>-1</sup>. These levels are lower than the best reported yields obtained using glucose as a carbon source, however the control *E. coli* production strain is unable to produce any  $\alpha$ -limonene in  $[C_2C_1Im][OAc]$  containing medium. To our knowledge this is the first demonstration of one-pot microbial  $\alpha$ -limonene production from IL-containing saccharified hydrolysate as the substrate.

We also established the genetic basis for the mutant *rcdA* phenotype. RcdA has mainly been studied for its involvement in the regulation of biofilm formation *via* CsgD. However, previous work by Shimada *et al.*<sup>33</sup> report a comprehensive list of its regulatory targets. In our study, two of these targets, *ybjj*

and *ompA*, were found to have a role in tolerance to imidazolium-based ILs, as a deletion of these genes led to increased sensitivity. OmpA is an abundant protein in the *E. coli* outer membrane and forms a non-specific channel.<sup>41</sup> An *E. coli*  $\Delta ompA$  mutant has been found to be more sensitive to compounds like sodium dodecyl sulfate, cholate, acid and to high osmolarity,<sup>47</sup> which correlate with sensitivity measured in our study to  $[C_2C_1Im]Cl$ . *ybjj* encodes an inner membrane protein belonging to the major facilitator superfamily (MFS) of pumps and is transcribed divergently from *rcdA*. Ybjj does not show any significant similarity to another MFS IL efflux pump, EilA, identified previously.<sup>18</sup> It has been shown that RcdA can function both as an activator and repressor of gene expression and our results indicate that RcdA functions as a transcriptional repressor for the expression of *ybjj* and *ompA* and is consistent with previous reports by Shimada *et al.*<sup>33</sup> that also show RcdA to be a repressor for *ybjj* expression. While the deletion of both *ybjj* and *ompA* increased the sensitivity to  $[C_2C_1Im]Cl$ , when overexpressed *in trans*, only Ybjj displayed the tolerance phenotype demonstrated by the *rcdA* mutant. These results indicate that the primary mechanism for enhanced IL tolerance in the RcdA(P7Q) mutant is due to the derepression of *ybjj*.

The second challenge for developing a one-pot biofuel production is in the direct use of pretreated, but unsaccharified biomass. This is possible by engineering the microbial host to also produce cellulases for the saccharification of pretreated biomass as has been shown before.<sup>15</sup> However, the recent improvements<sup>7</sup> in processes using ILs allow greater residual IL levels to be retained in the final substrate necessitating that the cellulase also be functional in the presence of ILs. To achieve this, we screened a mini-library of previously reported IL tolerant cellulases for their ability to grow on PASC, in the presence or absence of IL. One enzyme, J29, emerged as a highly active and IL-tolerant cellulase in the conditions used to cultivate *E. coli* for bio-fuel production. J29 has been shown to be 100% active in 294 mM  $[C_2C_1Im][OAc]$  and retains >50% activity in 882 mM  $[C_2C_1Im][OAc]$ .<sup>9</sup> While its optimal temperature is reported to be 65 °C, we found its activity to be sufficient at 30 °C, the optimal temperature for  $\alpha$ -limonene production by *E. coli* DH1. A future study focused on the full biochemical characterization of the cellulases in our library will be very valuable in determining the underlying mechanism for the superior performance of J29 relative to the other enzymes and may use methods that were developed to examine cellulases after exposure to reagents such as  $[C_2C_1Im][OAc]$ .<sup>48</sup>

We consolidated an *E. coli* DHI *rcdA* mutant background with a plasmid borne  $\alpha$ -limonene production pathway and the plasmid pCellulose-J29, and demonstrated the production of 10 mg per L  $\alpha$ -limonene on growth medium containing PASC as carbon source in the presence of 100 mM  $[C_2C_1Im][OAc]$ . This yield is significantly lower than the best  $\alpha$ -limonene production reported using idealized glucose based growth conditions. However the demonstrated one-pot biofuel production from non-saccharified cellulose provides the necessary next step in the development of a strain that can function and



produce a biofuel product in a highly industrially relevant condition.

Several challenges remain to be overcome as we continue to build and test strains and production processes with greater industrial value. The growth benefit provided by the *rcdA* mutant, *via* the derepression of *ybjj*, can be further optimized by fine-tuning the levels of this MFS pump as well as by combining additional IL tolerance genes. In this study we also do not address the presence of other potentially inhibiting compounds in the growth medium (for example, lignin derived aromatic compounds)<sup>49</sup> and the toxicity of the final product itself,<sup>50–52</sup> both of which are factors that likely negatively impact fuel production. Tolerance mechanisms for many of these inhibitory compounds have been studied and reported and often involve export pumps,<sup>53,54</sup> and pose their own metabolic burden on the cell when overexpressed.<sup>55</sup> Our group and others have shown in previous studies that the overexpression of pumps needs to be tightly controlled.<sup>19,50</sup> One foreseeable challenge is to fully understand how different tolerance mechanisms can be combined in a synergistic manner. Other areas for the successful development of a consolidated biofuel process include the improved secretion of cellulases and continued metabolic engineering of the fuel pathways, that when incorporated into the microbial chromosome will generate the final industrial hosts.

## Acknowledgements

We thank Noppadon Sathitsuksanoh (JBEI) for providing PASC, Ling Liang and Tina Trang Luong (ABPDU) for their effort in hydrolysate preparation, and Wendy Schackwitz (US DOE Joint Genome Institute) for the genome re-sequencing and data analysis support for the mutant *E. coli* strain FM0002. This work was part of the DOE Joint BioEnergy Institute (<http://www.jbei.org>) supported by the U. S. Department of Energy, Office of Science, Office of Biological and Environmental Research, through contract DE-AC02-05CH11231 between Lawrence Berkeley National Laboratory and the U. S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes.

## References

- 1 D. Tilman, R. Socolow, J. A. Foley, J. Hill, E. Larson, L. Lynd, S. Pacala, J. Reilly, T. Searchinger, C. Somerville and R. Williams, *Science*, 2009, **325**, 270–271.
- 2 V. Chaturvedi and P. Verma, *Biotech.*, 2013, **3**, 415–431.
- 3 M. Mora-Pale, L. Meli, T. V. Doherty, R. J. Linhardt and J. S. Dordick, *Biotechnol. Bioeng.*, 2011, **108**, 1229–1245.
- 4 C. Li, B. Knierim, C. Manisseri, R. Arora, H. V. Scheller, M. Auer, K. P. Vogel, B. A. Simmons and S. Singh, *Bioresour. Technol.*, 2010, **101**, 4900–4906.
- 5 C.-Z. Liu, F. Wang, A. R. Stiles and C. Guo, *Appl. Energy*, 2012, **92**, 406–414.
- 6 D. Klein-Marcuschamer, B. A. Simmons and H. W. Blanch, *Biofuels, Bioprod. Biorefin.*, 2011, **5**, 562–569.
- 7 N. M. Konda, J. Shi, S. Singh, H. W. Blanch, B. A. Simmons and D. Klein-Marcuschamer, *Biotechnol. Biofuels*, 2014, **7**, 86.
- 8 J. I. Khudyakov, P. D'haeseleer, S. E. Borglin, K. M. Deangelis, H. Woo, E. A. Lindquist, T. C. Hazen, B. A. Simmons and M. P. Thelen, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, E2173–E2182.
- 9 J. M. Gladden, J. I. Park, J. Bergmann, V. Reyes-Ortiz, P. D'haeseleer, B. F. Quirino, K. L. Sale, B. A. Simmons and S. W. Singer, *Biotechnol. Biofuels*, 2014, **7**, 15.
- 10 J. I. Park, E. J. Steen, H. Burd, S. S. Evans, A. M. Redding-Johnson, T. Batth, P. I. Benke, P. D'haeseleer, N. Sun, K. L. Sale, J. D. Keasling, T. S. Lee, C. J. Petzold, A. Mukhopadhyay, S. W. Singer, B. A. Simmons and J. M. Gladden, *PLoS One*, 2012, **7**, e37010.
- 11 D. Gao, Y. Luan, Q. Wang, Q. Liang and Q. Qi, *Microb. Cell Fact.*, 2015, **14**, 159.
- 12 S. M. Gaida, A. Liedtke, A. H. W. Jentges, B. Engels and S. Jennewein, *Microb. Cell Fact.*, 2016, **15**, 6.
- 13 L. R. Lynd, W. H. van Zyl, J. E. McBride and M. Laser, *Curr. Opin. Biotechnol.*, 2005, **16**, 577–583.
- 14 D. La Grange, R. Den Haan and W. Van Zyl, *Appl. Microbiol.*, 2010, **87**, 1195–1208.
- 15 G. Bokinsky, P. P. Peralta-Yahya, A. George, B. M. Holmes, E. J. Steen, J. Dietrich, T. Soon Lee, D. Tullman-Ercek, C. A. Voigt, B. A. Simmons and J. D. Keasling, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 19949–19954.
- 16 A. Mukhopadhyay, N. J. Hillson and J. D. Keasling, *Microbial Stress Tolerance for Biofuels: Systems Biology*, Springer Science & Business Media, 2011.
- 17 M. Ouellet, S. Datta, D. C. Dibble, P. R. Tamrakar, P. I. Benke, C. Li, S. Singh, K. L. Sale, P. D. Adams, J. D. Keasling, B. A. Simmons, B. M. Holmes and A. Mukhopadhyay, *Green Chem.*, 2011, **13**, 2743.
- 18 T. L. Ruegg, E.-M. Kim, B. A. Simmons, J. D. Keasling, S. W. Singer, T. S. Lee and M. P. Thelen, *Nat. Commun.*, 2014, **5**, 3490.
- 19 M. Frederix, K. Hütter, J. Leu, T. S. Batth, W. J. Turner, T. L. Ruegg, H. W. Blanch, B. A. Simmons, P. D. Adams, J. D. Keasling, M. P. Thelen, M. J. Dunlop, C. J. Petzold and A. Mukhopadhyay, *PLoS One*, 2014, **9**, e101115.
- 20 J. Alonso-Gutierrez, R. Chan, T. S. Batth, P. D. Adams, J. D. Keasling, C. J. Petzold and T. S. Lee, *Metab. Eng.*, 2013, **19**, 33–41.
- 21 P. P. Peralta-Yahya, F. Zhang, S. B. del Cardayre and J. D. Keasling, *Nature*, 2012, **488**, 320–328.
- 22 B. G. Harvey, M. E. Wright and R. L. Quintana, *Energy Fuels*, 2010, **24**, 267–273.
- 23 T. S. Ham, Z. Dmytriv, H. Plahar, J. Chen, N. J. Hillson and J. D. Keasling, *Nucleic Acids Res.*, 2012, **40**, e141.



- 24 T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K. A. Datsenko, M. Tomita, B. L. Wanner and H. Mori, *Mol. Syst. Biol.*, 2006, **2**, 2006.0008.
- 25 P. P. Cherepanov and W. Wackernagel, *Gene*, 1995, **158**, 9–14.
- 26 K. A. Datsenko and B. L. Wanner, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 6640–6645.
- 27 N. J. Hillson, R. D. Rosengarten and J. D. Keasling, *ACS Synth. Biol.*, 2012, **1**, 14–21.
- 28 D. G. Gibson, L. Young, R.-Y. Chuang, J. C. Venter, C. A. Hutchison and H. O. Smith, *Nat. Methods*, 2009, **6**, 343–345.
- 29 K. Deng, J. M. Guenther, J. Gao, B. P. Bowen, H. Tran, V. Reyes-Ortiz, X. Cheng, N. Sathitsuksanoh, R. Heins, T. E. Takasuka, L. F. Bergeman, H. Geertz-Hansen, S. Deutsch, D. Loqué, K. L. Sale, B. A. Simmons, P. D. Adams, A. K. Singh, B. G. Fox and T. R. Northen, *Front. Bioeng. Biotechnol.*, 2015, **3**, 153.
- 30 H. Li and R. Durbin, *Bioinformatics*, 2009, **25**, 1754–1760.
- 31 H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis and R. Durbin, *Bioinformatics*, 2009, **25**, 2078–2079.
- 32 C. Li, D. Tanjore, W. He, J. Wong, J. L. Gardner, K. L. Sale, B. A. Simmons and S. Singh, *Biotechnol. Biofuels*, 2013, **6**, 1–14.
- 33 T. Shimada, Y. Katayama, S. Kawakita, H. Ogasawara, M. Nakano, K. Yamamoto and A. Ishihama, *Microbiology-Open*, 2012, **1**, 381–394.
- 34 H. Yang, E. Wolff, M. Kim, A. Diep and J. H. Miller, *Mol. Microbiol.*, 2004, **53**, 283–295.
- 35 Y. Nakasone, T. Ono, A. Ishii, S. Masuda and M. Terazima, *Biochemistry*, 2010, **49**, 2288–2296.
- 36 J. Lee, S. R. Hiibel, K. F. Reardon and T. K. Wood, *J. Appl. Microbiol.*, 2010, **108**, 2088–2102.
- 37 V. Seputiene, D. Motiejūnas, K. Suziedelis, H. Tomenius, S. Normark, O. Melefors and E. Suziedeliene, *J. Bacteriol.*, 2003, **185**, 2475–2484.
- 38 M. Hammar, A. Arnqvist, Z. Bian, A. Olsén and S. Normark, *Mol. Microbiol.*, 1995, **18**, 661–670.
- 39 C.-G. Korea, R. Badouraly, M.-C. Prevost, J.-M. Ghigo and C. Beloin, *Environ. Microbiol.*, 2010, **12**, 1957–1977.
- 40 C. J. Dorman and C. F. Higgins, *J. Bacteriol.*, 1987, **169**, 3840–3843.
- 41 E. Sugawara and H. Nikaïdo, *J. Biol. Chem.*, 1992, **267**, 2507–2511.
- 42 Y. Itoh, J. D. Rice, C. Goller, A. Pannuri, J. Taylor, J. Meisner, T. J. Beveridge, J. F. Preston and T. Romeo, *J. Bacteriol.*, 2008, **190**, 3670–3680.
- 43 C. Wirth, G. Condemine, C. Boiteux, S. Bernèche, T. Schirmer and C. M. Peneff, *J. Mol. Biol.*, 2009, **394**, 718–731.
- 44 A. M. Redding-Johanson, T. S. Bath, R. Chan, R. Krupa, H. L. Szmîdt, P. D. Adams, J. D. Keasling, T. S. Lee, A. Mukhopadhyay and C. J. Petzold, *Metab. Eng.*, 2011, **13**, 194–203.
- 45 N. Sun, H. Liu, N. Sathitsuksanoh, V. Stavila, M. Sawant, A. Bonito, K. Tran, A. George, K. Sale and S. Singh, *Biotechnol. Biofuels*, 2013, **6**(1), 39.
- 46 J. I. Park, M. S. Kent, S. Datta, B. M. Holmes, Z. Huang, B. A. Simmons, K. L. Sale and R. Sapra, *Bioresour. Technol.*, 2011, **102**, 5988–5994.
- 47 Y. Wang, *Biochem. Biophys. Res. Commun.*, 2002, **292**, 396–401.
- 48 E. Husson, S. Buchoux, C. Avondo, D. Cailleu, K. Djellab, I. Gosselin, O. Wattraint and C. Sarazin, *Bioresour. Technol.*, 2011, **102**, 7335–7342.
- 49 L. J. Jönsson, B. Alriksson and N.-O. Nilvebrant, *Biotechnol. Biofuels*, 2013, **6**, 16.
- 50 M. J. Dunlop, J. D. Keasling and A. Mukhopadhyay, *Synth. Biol.*, 2010, **4**, 95–104.
- 51 M. J. Dunlop, Z. Y. Dossani, H. L. Szmîdt, H. C. Chu, T. S. Lee, J. D. Keasling, M. Z. Hadi and A. Mukhopadhyay, *Mol. Syst. Biol.*, 2011, **7**, 487.
- 52 J. L. Foo, H. M. Jensen, R. H. Dahl, K. George, J. D. Keasling, T. S. Lee, S. Leong and A. Mukhopadhyay, *mBio*, 2014, **5**, e01932.
- 53 P. Fernandes, B. S. Ferreira and J. M. S. Cabral, *Int. J. Antimicrob. Agents*, 2003, **22**, 211–216.
- 54 A. Mukhopadhyay, *Trends Microbiol.*, 2015, **23**, 498–508.
- 55 S. Wagner, L. Baars, A. J. Ytterberg, A. Klussmeier, C. S. Wagner, O. Nord, P.-A. Nygren, K. J. van Wijk and J.-W. de Gier, *Mol. Cell. Proteomics*, 2007, **6**, 1527–1550.
- 56 T. S. Lee, R. A. Krupa, F. Zhang, M. Hajimorad, W. J. Holtz, N. Prasad, S. K. Lee and J. D. Keasling, *J. Biol. Eng.*, 2011, **5**, 12.

